Glaucoma Clinical Trial
Official title:
Blood Flow of Ophthalmic Artery and Its Relationship to Structural Properties of the Optic Nerve and Intraocular Pressure in Glaucoma
The main purpose of this project is to investigate the blood flow of the ophthalmic artery (OA) in patients with ocular hypertension, high tension glaucoma and normal tension glaucoma. It is also to study the influence of the intraocular pressure difference on OA blood flow in the two first groups. Furthermore, the investigators want to understand the relationship between ocular dynamics, blood flow and structural alternations of the optic nerve head (ONH). The rationale behind the study is to improve knowledge of the pathogenesis of glaucoma.
The investigators will investigate the OA blood flow, intraocular pressure (IOP) and
structural properties of the optic nerve. The investigators will include glaucoma patients as
they believe that glaucoma may be caused by or influenced by OA blood flow. The investigators
will include also patients with intraocular hypertension with and without pseudoexfoliation
in order to study how changes in IOP interact with OA blood flow and the structural
properties of the optic nerve in a group that does not develop glaucoma. In addition, the
investigators will investigate patients that develop glaucoma in spite of a normal IOP.
Therefore, the investigators will study three fundamentally different groups (G1, G2 and G3)
of patients as well as a control group of healthy subjects (G4):
G1: Newly diagnosed and untreated Glaucoma (optic and visual field damage exists).
G2: Ocular hypertension with IOP ≥ 23 mmHg (i.e. only elevated eye pressure).
G3: Normal Tension Glaucoma.
G4: Healthy subjects.
Each group will include 25 patients apart from G2 where 50 patients will be included, half of
which have pseudoexfoliation syndrome. The study will be performed in accordance with the
tenets of the Helsinki Declaration and is approved by the regional ethical board.
Study protocol overview:
Study protocol consists of two parts of examinations repeated with approximately one week
between: Each part is divided into two examinations; one at the Department of radiology
followed by one at the Department of ophthalmology. The measurements are repeated
approximately one week later for G1 and G2.
Day 1: First, MRI scans on the brain to measure the blood flow of OA as well as the
structural and morphological properties of the ON (see method below). Second, just after MRI
examination, the patient will be examined at the Department of ophthalmology. Measurement of
intraocular pressure, ocular pulse amplitude, central corneal thickness, bulb length,
investigation with optical coherence tomography (OCT) and blood pressure will be performed.
The patients from G3 (Normal Pressure Glaucoma) will participate only in Day 1, since most
cases already has pressure-lowering treatment. Also subjects in G4 vill only participate in
Day 1. All other participants will receive pressure lowering drug (Latanoprost) in one eye
once daily, until the protocol is repeated at Day 2.
Day 2: The measurements at Day 1 are repeated approximately one week later. The measurements
will be made in both eyes, which is why an eye can serve as a control. That way the
investigators will have a good opportunity to assess how much of the change the investigators
see in the treated eye that may be due to normal variations in OA blood flow and how much
depends on the given treatment.
The findings will be compared between the groups and to the normal material in G4. The
investigators will be able to see whether, and if so, to what extent, eyes with glaucoma
differ from normal eyes in terms of blood flow through OA as compared to the IOP
measurements, and different biomechanical parameters of the eye. Thus, determine the pressure
dynamics and calculate ocular compliance with the three different groups of research
subjects; newly diagnosed glaucoma, ocular hypertension, normal tension glaucoma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |